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A Comparison of Exhaled Breath Nitric Oxide Between Older and Younger 
Individuals 
 
Robert L. Gordon, Jr., M.D. 
ABSTRACT 
BACKGROUND: Older individuals suffer from higher rates of pulmonary 
infections than younger individuals.  In addition, older individuals have increased 
morbidity and mortality due to pulmonary infections when compared to younger 
individuals.  The physiological and immunological reasons for these 
aforementioned differences are not clear.  Recently, non-invasive markers of the 
lung’s physiologic and immunologic status have been recognized.  This study 
employs one of these non-invasive markers, exhaled nitric oxide, in an attempt to 
determine how the airways may change with age, predisposing older individuals 
to pulmonary diseases and poorer outcomes as compared to younger 
individuals. 
METHODS: Exhaled nitric oxide measurements were obtained from a group of 
25 older subjects (61 to 79 years old, median 72 years old) and a group of 23 
younger subjects (21 to 30 years old, median 24 years old) that were non-
smokers with no history of pulmonary disease, no recent respiratory infections, 
and no history of environmental allergies. A focused history and physical exam 
along with spirometry were used to confirm the normal pulmonary status of each 
subject. Exhaled nitric oxide was measured following the American Thoracic 
vi 
Society recommendations using the Sievers Nitric Oxide Analyzer 280i. The 
exhaled nitric oxide values for the old and young groups were compared using 
the Wilcoxon Rank Sum test.  
RESULTS: For the older subjects, the median exhaled NO concentration was 
36.9 ppb. For the younger subjects, the median exhaled NO concentration was 
18.7 ppb.  These exhaled NO concentrations are significantly different  
(p = 0.0011). 
CONCLUSIONS: The exhaled NO concentrations are significantly higher in older 
individuals than in younger individuals. The reasons for this difference along with 
the significance are unclear and further studies will be necessary to further 
evaluate these issues.
1 
 
 
 
 
 
Introduction 
 
Background 
Respiratory infections, particularly pneumonia, are known to cause 
significant morbidity and mortality in the elderly population.1, 2  The incidence of 
pneumonia has been shown to increase with age with incidences of 91.6/100,000 
for individuals younger than 45 years of age, 277.2/100,000 for individuals aged 
45 to 64 years, and 1012.3/100,000 for individuals older than 65 years in one 
study.3 
Factors that are known to predispose the elderly to pneumonia are vast 
and include: age greater than 65 years, underlying comorbid illnesses such as 
chronic obstructive pulmonary disease, diabetes mellitus, congestive heart 
failure, malignancy, poor nutrition, institutionalization, recent hospitalization, and 
smoking.1, 4  It is evident, as individuals increase in age, they acquire more of the 
aforementioned risk factors bringing into question whether increasing age itself is 
an independent risk factor for developing pneumonia.   
Aging in itself has been shown to lead to physiological and immunological 
changes that may predispose the aged population to pneumonia and poorer 
outcomes once contracted.  The physiological changes include: impaired 
mucociliary transport, enhanced oropharyngeal colonization, increased aspiration 
potential, decreased ability to expectorate, decreased respiratory muscle 
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endurance, and decreased forced expiratory volume in one second (FEV1).1, 4  
Although not fully elucidated, the immune system has been shown to undergo 
alterations as individuals age such that there is impaired immune surveillance, 
decreased ability to mount an appropriate immune response, and inappropriate 
immune responses.5  
Exhaled respiratory markers have been recognized that correlate with 
infection and inflammation.6  These include nitric oxide (NO), airway pH, 
eicosanoids, hydrogen peroxide, hydrocarbons, carbon monoxide, and NO-
related products.6 
NO has been studied extensively since Gustafsson recognized that it was 
present in exhaled breath.7  As will be discussed later, NO has many 
immunological and physiological roles within the human.  In particular, NO has 
been found to be positively correlated with inflammation and infection within the 
lower respiratory tract.6, 8-10 
This study was conducted to determine if there is a difference in 
endogenous NO concentrations derived from the lower respiratory airways 
between younger and older individuals in an attempt to see how the airways may 
change with age, predisposing the older population to pulmonary infections and 
increased morbidity and mortality with pulmonary infections.  Other studies have 
not shown a difference between these two groups, however, those studies have 
generally included less people, particularly older individuals.11-13 
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Airway Nitric Oxide 
 
Biochemistry 
 NO is a free-radical which is formed enzymatically and non-enzymatically.  
NO itself is very reactive and undergoes a multitude of reactions with other 
molecules within the human respiratory tract to produce other compounds with 
varying functions.   
NO may be formed when L-arginine is oxidized producing NO and L-
citrulline.  This reaction is catalyzed by a group of three enzymes known as nitric 
oxide synthases (NOSs) with the assistance of various co-factors.  NOSs are 
divided into constitutive and inducible types.  There are two types of constitutive 
NOS (cNOS) which are known as Type I or neuronal NOS (nNOS) and Type III 
or endothelial NOS (eNOS). These enzymes are dependent on calcium and 
calmodulin for activation.  There is one type of inducible NOS known as Type II 
or inducible NOS (iNOS) which is not dependent on calcium and calmodulin for 
activation. 
NO is also produced non-enzymatically within the airways.  One method is 
via nitrite (NO2-) protonation to form nitrous acid (HNO2) which then releases NO 
gas when an acidic environment is present such as during an asthma 
exacerbation.14  Another source of NO is via the release of NO from  
S-nitrosothiols within the airway tissues.6, 15  The nitrosothiols are originally 
produced by NO reacting with thiol groups (RSH) to produce the nitrosothiols 
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(RS-NO). The nitrosothiols are excellent carriers of NO and provide it 
stabilization to act at distant sites from production.16   
Nitric oxide is highly reactive with other molecules besides the thiols.  
When NO combines with the superoxide anion, peroxynitrite (OONO-) 
is formed.16  This molecule is a pro-oxidant and is known to be toxic to many 
molecules such as nucleic acids, lipids, and proteins.16, 17  Also, it is known to be 
very toxic to microbes.6, 17  In addition, NO reacts with O2 to form nitrite and 
nitrate in aqueous solutions by reactions catalyzed by transition metals such as 
iron.9, 17  NO also reacts with the heme moiety of hemoglobin to form 
methemoglobin.17   
 
Cellular and Anatomic Sources of the Nitric Oxide Synthases 
 All three of the nitric oxide synthases have been identified in airway 
mucosa.18   Neuronal NOS has been found in neurons, bronchial epithelial cells, 
and skeletal muscles.9, 19  Endothelial NOS has been localized to platelets, 
endothelial cells, endocardial cells, bronchial epithelial cells, and myocardial  
cells.9, 20  Inducible NOS has been demonstrated in the epithelial linings of the 
airways, macrophages, neutrophils, eosinophils, and fibroblasts.9, 17  As has been 
described above, the cNOSs are calcium/calmodulin dependent for activation 
whereas iNOS is not dependent on calcium/calmodulin for activation.  Inducible 
NOS is induced indirectly by inflammatory cytokines such as interferon gamma 
(IFN-γ), interleukin (IL) – 1 β, tumor necrosis factor – alpha (TNF-α), and others.  
The inflammatory cytokines induce the production of transcription factors such 
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and nuclear factor- kappa B (NF-κB) and signal transducers and activators of 
transcription-1 (STAT-1) which in turn lead to the transcription of the iNOS gene 
sequence.21-24  It is of note that iNOS produces up to 1,000 times more NO than 
cNOS and that cellular production continues for hours after the  
stimulus.22  In addition, iNOs has now been shown to be expressed at low levels 
constitutively in airway epithelium.25 
 As mentioned earlier, all three of the enzymes are produced within the 
airways.  However the upper airways need to be distinguished from the lower 
airways with regards to synthase activity and NO levels.  The upper airways, 
which include the paranasal sinuses and nose, have been shown to produce 
several fold higher levels of NO than the lower airways.22, 26, 27  The type of 
synthase in these areas is genotypically similar to iNOS of the lower airways.26  
However, it is expressed at relatively high levels constitutively.26, 28  The lower 
airways are capable of producing NO via all three types of synthases.  For years 
there was great debate over where the majority of the exhaled NO was derived 
from within the lower airways.  It has now been determined that the majority of 
the exhaled NO is derived from the airways proximal to the alveoli.29 
 
Function of Endogenous Nitric Oxide within the Lower Respiratory Tract 
 Nitric oxide is a mediator, either directly or via other NO containing 
reaction products for the nonadrenergic, noncholinergic (NANC) neural inhibitory 
impulses from nerves innervating the respiratory tract.30  Neuronal NOS is the 
synthase which is involved in the production of NO for this neural function. The 
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NANC neural pathways are the only bronchodilatory pathways in the airways of 
humans.31  It has been postulated that the bronchodilatory effect mediated by the 
NANC neural impulses is important in balancing cholinergic bronchoconstriction 
rather than causing significant independent bronchodilatation.32  The 
bronchodilatory effect mediated by NO or NO containing products is via 
stimulation of the intracellular enzyme guanylate cyclase which catalyzes the 
conversion of guanylate triphosphate (GTP) to  cyclic guanylate 3’5’ 
monophosphate (cGMP) which ultimately leads to relaxation of the smooth 
muscles within the airways.9  
 NO and NO containing products are involved in vasodilatation in the 
pulmonary and bronchial circulations.33, 34  Endothelial NOS is the synthase 
which is involved in the production of NO for this vasodilatory function at 
baseline.  The vasodilatation is mediated in a similar fashion as the 
bronchodilatation. 
When present in abnormally elevated amounts, NO is a mediator that is 
involved in the inflammatory process in multiple ways.  Inducible NOS is the 
synthase responsible for production of NO in very large quantities which 
contribute to an inflammatory response.  NO, due to its vasodilatory properties, 
causes exaggerated vasodilatation along with plasma exudation carrying 
inflammatory cytokines and cells to specific sites within the lung to cause or 
perpetuate an inflammatory response.9 
NO, through an intermediary, peroxynitrite, may lead to significant 
inflammation within the airways through its oxidizing effects on tissues within the 
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lungs.35  In addition, because of its toxic effect on microbes, it may serve as an 
innate defense mechanism within the lung.17 
 NO has also been shown to accentuate inflammation by modulating the 
immune system.  It is believed that NO may selectively inhibit T-helper 1 (Th1) 
lymphocytes.36  This in turn may lead to decreased levels of IFN-γ which is 
produced by the Th1 lymphocytes.  As a result of decreased levels of IFN-γ, Th2 
cells proliferate liberating substantial amounts IL-5 which drive eosinophilic 
inflammation in conditions such as asthma.36-38  This effect is most prominent 
when elevated levels of NO are present after induction of iNOS. 
 NO has also been shown to mediate ciliary motion and stimulate airway 
secretions.39  In individuals with primary ciliary dyskinesia (PCD), exhaled NO 
values have been shown to be very low.  This is significant as only PCD has 
such a characteristically low exhaled NO value.40 
 As can be appreciated from the above discussion regarding NO 
production and function, NO’s roles and the roles of the synthases are quite 
complex.  Due to its many functions, NO may therefore have beneficial or 
deleterious effects depending on the underlying situation within the lung. 
 
Clinical Significance of Nitric Oxide 
Nitric oxide is present in the airways of healthy individuals and individuals 
with various airway diseases.  In addition, all three of the synthases are produced 
in both healthy individuals and those with airway diseases.6, 25  The expression of 
iNOS in the lower airways of healthy individuals had long been debated but there 
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is now evidence that it is indeed expressed at a basal rate, ramping up when it is 
specifically induced by inflammatory cytokines involved in various airway 
diseases resulting in elevated exhaled NO levels.25  NO has been studied 
extensively in individuals with airway conditions as a potential marker for 
inflammation.  Many believe that this marker will revolutionize the non-invasive 
monitoring of airway diseases.  
Exhaled NO has been studied most extensively in asthmatics.  Elevated 
levels of exhaled NO in asthmatics have been well documented in the  
literature.41, 42  This rise in NO is believed to be related to the increased 
expression of iNOS due to an inflammatory state via inflammatory cytokines and 
to the non-enzymatic production of NO from nitrite in the acidic bronchial 
environment of asthmatics.14, 43  This marker is not specific for asthma but may 
assist in differentiating healthy individuals from asthmatics when there is a 
question.44  Another potential use of NO in asthmatics is for the monitoring of 
corticosteroid and/or anti-leukotriene therapies.  Levels of NO have been shown 
to decline in asthmatics treated with corticosteroids (inhaled and oral) along with 
the leukotriene inhibitors.45-48  The reason for the decline associated with 
corticosteroids has been postulated to be due to decreased iNOS levels 
secondary to inhibition of iNOS transcription factors such as NF-κB and a 
reduction of inflammatory cytokines.45, 49  In addition, exhaled NO has been 
shown to increase before other markers of asthma exacerbation such as lung 
function, provocative concentration 20% (PC20), sputum eosinophilia, or asthma 
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symptoms.50  Due to this ability, it has been proposed that NO levels may be 
followed to determine the “loss of control” of asthma.50   
Exhaled nitric oxide has also been shown to be elevated in other disease 
states.  Adrie et al. described elevated exhaled nitric oxide levels in mechanically 
ventilated patients with pneumonia.10  In addition, individuals with unstable 
chronic obstructive disease, bronchiectasis, and exposure to outdoor pollutants 
have also been shown to have elevated levels of exhaled NO.51, 52  Elevated 
exhaled nitric oxide levels have also been demonstrated in individuals given L-
arginine orally or via inhalation, and during exercise.51-55  Table 1 summarizes 
the conditions in which exhaled NO may be increased. 
Exhaled nitric oxide has been shown to be decreased in various 
respiratory disease states and include: cystic fibrosis, PCD, and pulmonary 
hypertension.51  Decreased exhaled nitric oxide levels have also been 
demonstrated in those who are smokers.  In addition, various drugs have been 
shown to reduce exhaled NO levels such as inhaled NOS inhibitors, oral or 
inhaled corticosteroids, anti-leukotriene medications, and alcohol.45-48, 51, 56, 57  
Table 1 summarizes the conditions in which exhaled NO may be decreased. 
 
Measurement of Nitric Oxide 
 The most commonly used method for detecting NO in exhaled breath is 
via chemiluminescence.  With this method, exhaled NO reacts with an excess of 
ozone (O3) within an exhaled breath NO analyzer to produce nitrogen dioxide 
(NO2) with an electron in the excited state (NO2*).  NO2* then transforms to the 
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ground state (NO2) while emitting electromagnetic radiation (chemiluminescence) 
ranging from 600-3,000 nm in wavelength.  This chemiluminescence is detected 
by a photomultiplier tube and is converted into an equivalent electrical display of 
NO concentration.  With this method, NO can be detected down to a 
concentration of less than 1 part per billion (ppb).  Refer to Figure 1 for the 
chemical reactions involved with the chemiluminescence method of measuring 
exhaled NO concentration.   
 
Table 1. Factors Which Influence Exhaled Nitric Oxide6, 58 
      Increased NO            Decreased NO 
 
Drugs: L-Arginine ingestion or 
inhalation, nitroprusside,  
ACE inhibitors 
 
 
Drugs: NOS inhibitors, oral or 
inhaled corticosteroids 
Respiratory tract infections Primary ciliary dyskinesis 
Sarcoidosis Pulmonary hypertension 
Asthma exacerbation Cystic Fibrosis 
Unstable COPD Smoking 
Bronchiectasis Alcohol ingestion 
Allergic/atopic state Forced exhalation 
Exercise Repeated spirometry 
Exposure to outdoor pollutants Sputum induction 
ACE = angiotensin converting enzyme; COPD = chronic obstructive pulmonary 
disease; NOS=nitric oxide synthase  
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Figure 1. The Chemical Reactions Involved in the Chemiluminescence Method 
  of Measuring Exhaled Nitric Oxide 
 
  
NO + 03 ? N02* + O2 
 
NO2* ? NO2 + hν 
 
 
 There are two types of exhaled NO collection methods which may be used 
in order to analyze the breath within an analyzer.  One method is called the “on-
line” method.  This method involves an individual exhaling a single breath into a 
mouthpiece which provides expiratory positive pressure against exhalation to 
prevent contamination of the sample by paranasal and nasal NO by closing the 
velopharyngeal aperture during the maneuver.  The mouthpiece is connected to 
the breath analyzer by tubing which immediately analyzes the breath for NO and 
provides a real-time read-out of the NO concentration.  The other method, known 
as the “off-line” measurement, involves an individual breathing continuously into 
a specialized bag via a mouthpiece for a defined amount of time.  After collection, 
the sample is then analyzed by the chemiluminescence machine. With this 
method the sample is analyzed at a later time. 
 The American Thoracic Society (ATS) and the European Respiratory 
Society (ERS) have both published extensive guidelines on the measurement of 
exhaled NO in an attempt to standardize the procedure.58, 59 
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Materials and Methods 
 
Study Design 
Individuals for two groups, a younger group and an older group, were 
recruited to participate in this study which was performed in the Breath Lab at the 
University of South Florida in Tampa, Florida.  Informed consent was obtained 
from each of the study participants prior to the conduction of the study after the 
research protocol along with the risks and benefits of the study were fully 
explained.  All personal information and data gathered in this study were done 
per the guidelines of the Health Insurance Portability and Accountability Act 
(HIPAA).  The Institutional Review Board at the University of South Florida 
approved the study protocol used for this particular study prior to its conduction. 
The study subjects consisted of an older group of 25 individuals (61 to 79 
years old, median 72 years old) and a younger group of 23 individuals (21 to 30 
years old, median 24 years old) that were non-smokers with no history of lung 
disease, no recent respiratory infections, and no history of environmental 
allergies.  A focused history using a questionnaire (Appendix A) and a physical 
exam were performed prior to beginning the testing to assess for any symptoms 
or signs of respiratory illness or impairment. None of the research participants 
had any symptoms or signs of respiratory illness or impairment that would have 
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excluded them from this study.  In addition, the subjects abstained from eating or 
drinking except for water for 6 hours prior to the study.  
Next, exhaled NO was assessed.  After the exhaled NO measurement, 
spirometry was performed to further confirm normal respiratory status.   
Spirometry was performed after the NO measurement as it has been show to 
affect the exhaled NO concentration if done prior to the exhaled NO 
assessment.58  After the spirometry, exhaled breath condensate (EBC) was 
obtained to assess the airway pH.  The methods for obtaining exhaled NO, 
spirometric, and EBC measurements will be described in detail later in the 
materials and methods section.  
 
Measurement of Exhaled Nitric Oxide 
 Exhaled NO measurements were performed in accordance with the 
protocol described by the ATS.58  The on-line measurements of exhaled NO were 
made using a chemiluminescence analyzer (Sievers, NOA™ 280i; Boulder, CO) 
with a response time of 67 msec which is sensitive to NO over a range of 
approximately 0.5 ppb to 500,000 ppb.  Standardization of the analyzer with the 
zero air filter (Sievers; Boulder, CO) containing KMnO4 and activated carbon and 
the calibration NO gas of 45 parts per million (ppm) (Sievers; Boulder, CO) were 
performed each day prior to use per the manufacturer’s recommendations. The 
chemiluminescence analyzer was connected to a personal computer that 
contained the NO analysis software (Sievers, NO Analysis™ Software Version 
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3.2; Boulder, CO) which provided a graphical display of exhaled flow rate and 
exhaled NO concentration during the analysis process. 
 Prior to the subject performing the test, the procedure was demonstrated 
by the examiner multiple times.  Next, the subject was seated in a comfortable 
manner such that he could view the attached computer monitor which displayed 
the real-time measurements of NO and flow rate so that biofeedback would be 
provided to assist in the acquisition of acceptable measurements.  The subject 
then inhaled through their mouth via the provided mouthpiece to total lung 
capacity (TLC).  The inspired air was filtered of room NO by a cartridge attached 
to the distal end of the mouthpiece.  Once reaching TLC, the subject exhaled in a 
continuous manner against resistance while maintaining the target ATS 
recommended exhalation flow rate of 50 ml/sec until a stable NO plateau of at 
least 3 seconds was obtained.58  After each maneuver, the subject was given a 
30 second break before performing the test again.58  Repeated exhalations were 
performed until three or more exhaled NO values were obtained that met ATS 
criteria and were within 5% of the mean to assure reproducibility.58  The resultant 
mean of these values was then taken to be the exhaled NO concentration for that 
subject.  Figure 2 depicts the NO analyzer and mouthpiece.  Figure 3 depicts the 
maneuver required for exhaled NO measurement.  
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Figure 2:  Sievers 280i Nitric Oxide Analyzer with Mouthpiece 
 
Figure 3: Performance of Exhaled Nitric Oxide Maneuver 
Mouthpiece with 
attached flowmeter
NO filtering 
cartridge 
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Spirometry 
 Spirometry was performed on each of the subjects using the Puritan-
Bennett, Renaissance II Spirometer (Carlsbad, CA) per ATS protocol.60  Forced 
expiratory volume in one second (FEV1) and forced expiratory volume in 6 
seconds (FEV6), a surrogate for forced vital capacity (FVC), were measured with 
the spirometer.61  In addition, the spirometer calculated the FEV1/FEV6 ratio.  
Hankinson’s spirometric reference values, which were incorporated into the 
spirometer, were used to determine if the subject’s spirometric values were within 
normal limits.62  In addition, the subjects’ FEV1/FEV6 ratio had to be equal to or 
greater than 70% in the younger group and equal to or greater than 65% in the 
older group to be considered normal for this study. 
 
Measurement of Exhaled Breath Condensate pH 
 Exhaled breath condensate collection and deaeration of the condensate 
were performed as has been described in the literature by using the RTube™ 
Exhaled Breath Condensate System (Respiratory Research, Inc; Charlottesville, 
VA) with the specialized pHTube™.63  In this procedure, the subject breathed 
normally into the specialized plastic pHTube™ which was surrounded by a 
cooling sleeve for 15 minutes while wearing nose clips.   Due to the surrounding 
cooling sleeve, the breath vapor was condensed into a breath condensate 
(liquid).  After obtaining the condensate, the sample was deaerated with argon 
gas by utilizing the Exhaled Breath Condensate System “standard plunger” to 
remove the carbon dioxide from the sample while monitoring the pH to assess for 
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stabilization of the pH using a pH meter (Denver Instrument Company, Model 
250 pH/Ion/Conductivity Meter; Arvada, CO).  Once the pH stabilized, that value 
was taken to be the pH of the condensate for that subject.  In addition, each of 
the condensate samples were tested spectrophotometrically (Thermo Spectronic, 
Genesys™ 2 Spectrophotometer; Rochester, NY)  for amylase to assure that 
there was no salivary contamination of the exhaled breath condensate using a 
specialized kit which assayed for α-amylase quantitatively in a kinetic fashion 
(Pointe Scientific, Inc., Liquid Amylase Reagent Set; Lincoln Park, MI).  Figure 4 
depicts the specialized tube used for collection of condensate.  Figure 5 depicts 
the process of measuring pH while the condensate sample is being deaerated 
with argon gas. 
 
Figure 4: pHTube Used to Collect Breath Condensate (Cooling Sleeve Not 
               Attached) 
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   Figure 5: Measurement of pH of Breath  
   Condensate While Undergoing Deaeration 
                with Argon Gas 
 
Statistical Analysis 
 The statistical software package JMP IN Version 5.1 (SAS Institute, Inc.; 
Cary, NC) was utilized to perform the statistical analysis.  The exhaled NO values 
and the exhaled breath condensate pH values were compared for the younger 
and older groups using the Wilcoxon Rank Sum test.  The Wilcoxon Rank Sum 
test was used to analyze the data because the frequency distributions of the data 
were found not to be normally distributed when plotted.  The Holm method was 
then applied to limit the chances of Type I error that may have been introduced 
due to multiple testing.64 
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Results 
 
Baseline Characteristics of the Study Populations 
 Twenty-three younger subjects were recruited with a median age of 24 
years and a range of 21 to 30 years.  Fourteen (61%) were females and 9 (39%) 
were males.  One individual in the younger group had ulcerative colitis.  The rest 
did not have any medical conditions.  Twenty-five older subjects were recruited 
with a median age of 72 years and a range of 61 to 79 years.  Eleven (44%) were 
females and 14 (56%) were males.  Health problems included: hypertension, 
coronary artery disease, hyperlipidemia, hypothyroidism, gastroesophageal reflux 
disease, and cancer.  Refer to Table 2 for a complete description of baseline 
characteristics of the study populations.  In addition, none of the individuals in 
either group had smoked within the past ten years, had been diagnosed with or 
had symptoms of allergies (allergic rhinitis or sinusitis), had been diagnosed with 
any lung disease including asthma, had a respiratory tract infection recently, or 
used anti-histamines recently.   
 
Spirometric Measurements 
Spirometric measurements are summarized in Table 3. 
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Table 2.  Baseline Characteristics of Study Populations 
Age Category Characteristic 
Old  (n =25) Young (n = 23) 
Gender Female (11) 44% 
Male (14) 56% 
Female (14) 61% 
Male (9) 39% 
Median age 72 years old 24 years old 
Health problems Hypertension (12) 48% 
CAD (3) 12% 
Hyperlipidemia (6) 24% 
Hypothyroidism (2) 8% 
GERD (2) 8% 
Cancer (2) 8% 
None (5) 20% 
None (22) 96% 
Ulcerative colitis (1) 4% 
Medications NSAIDs/ ASA (10) 40% 
Vitamins and minerals 
   (12) 48% 
Statins (6) 24% 
ACE inhibitors (5) 20% 
PPIs (2) 8% 
Synthroid (2) 8% 
None (1) 4% 
Birth control pill (6) 26% 
Imuran (1) 4% 
Antibiotic (1) 4% 
Vitamins and minerals 
   (1) 4% 
None (15) 65% 
History of tobacco use 
(>10 years ago) 
Yes (16) 64% 
No (9) 36% 
Yes (2) 9% 
No (21) 91% 
Occupation Retired (19) 76% 
Nurse (1) 4% 
Professor (3) 12% 
Restaurant manager (1) 
   4% 
Adm. assistant (4) 17% 
Nurse (3) 13% 
Student (16) 70% 
Exposure to secondary 
smoke 
Yes (3) 12% 
No (22) 88% 
Yes (1) 4% 
No (22) 96% 
Past exposures Firefighter (1) 4% 
Coal dust, coke oven (1) 
   4% 
None (23) 92% 
Chlorine gas (1) 4% 
None (22) 96% 
CAD = coronary artery disease; GERD = gastroesophageal reflux disease; 
NSAIDs/ASA = nonsteroidal anti-inflammatory drugs / aspirin; PPIs = proton 
pump inhibitors; Adm. assistant = administrative assistant. 
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Table 3.  Spirometric Measurements of Study Populations 
 
Age Category Measurement 
Old Young 
Median FEV1 
(percentage of normal) 
94% 95% 
Median FEV6 
(percentage of normal) 
95% 92% 
Median FEV1/ FEV6 78% 87% 
FEV1 = forced expiratory volume in 1 second; FEV6 = forced expiratory volume in 
6 seconds 
 
 
Exhaled Breath Condensate pH Measurements 
 The median deaerated pHs for each of the groups are depicted in Table 4.  
The range of pH for the older group was 5.26 to 8.12.  The range for the pH for 
the younger group was 6.44 to 8.12.  The median pHs of the older age group and 
the younger age group were both 7.72.  
 
Exhaled Nitric Oxide Measurements 
 The median exhaled nitric oxide concentrations for each of the groups are 
depicted in Table 4.  The range for exhaled NO for the older group was 6.0 ppb 
to 103 ppb.  The range for exhaled for NO for the younger group was 6.4 ppb to 
214 ppb.  The median exhaled NO concentrations of the older and younger age 
groups were 36.9 ppb and 18.7 ppb, respectively. 
 
Table 4.  Exhaled Breath Nitric Oxide and Exhaled Breath Condensate 
Deaerated pH  
 
Measurement Median for Old Median for Young P Value  
 
Deaerated pH 7.72 7.72 0.959 
Nitric Oxide (ppb) 36.9 18.7 0.0011 
ppb=parts per billion 
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Discussion 
 
 Exhaled NO has been shown to be elevated in lower respiratory 
conditions in which inflammation is present such as asthma and pneumonia.  
Two mechanisms are thought to be responsible for the increase in NO. One is 
the up-regulation of iNOS due to inflammatory cytokines and the other is due to 
an increased release of NO from molecular intermediates due to an acidic  
airway.14, 43  Despite the uncertainty with regards to the mechanism of NO 
elaboration from the lower airways, exhaled NO has the potential for assisting in 
the diagnosis and prognosis of airway diseases and monitoring their treatments. 
 The current study compared NO concentrations between a younger group 
of 23 individuals (median age of 24 years) and an older group of 25 individuals 
(median age of 72 years) that were non-smokers with no history of pulmonary 
disease, no recent respiratory infections, and no history of environmental 
allergies.  This study was conducted to determine if there is a difference in 
endogenous NO concentrations derived from the lower respiratory airways 
between younger and older individuals in an attempt to see how the airways may 
change with age, predisposing the older population to pulmonary infections and 
increased morbidity and mortality with pulmonary infections. 
 This study showed that exhaled NO concentrations of the older and 
younger age groups were 36.9 ppb and 18.7 ppb, respectively.  This represented 
a significant statistical difference between the two groups with a ρ value of 
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0.0011 per the Wilcoxon Rank Sum test.  This statistical significance held true 
when adjusted for multiple testing with the Holm method.  In addition, there was 
no significant difference between the exhaled breath condensate pHs between 
the two groups with each having a median of 7.72.   
 This is the first study to show a significant difference in exhaled NO 
between a younger and an older population.  Previous studies have not shown a 
difference.  Ekroos et al. found no correlation between age and NO.11  However, 
the age range was 21-48 years and the majority of the subjects were in their 
twenties and thirties.   Their study did not really address a possible difference 
between a young population and an aged population due to its limited age 
sampling.  Tsang et al. studied a group of 121 healthy adults with an age range 
of 20-79 years and did not find a relationship between age and NO levels.13  On 
evaluation of their data, there were noted to be several high NO outliers in the 
younger age ranges that may have significantly affected their data.  In addition, 
Tsang et al. did not divide their sample into two distinct groups in order to 
analyze for a difference as was done in this study using the Wilcoxon Rank Sum 
test.  Instead, they looked for a correlation using regression.  With their method, 
a linear relationship would have been necessary to reveal a difference as 
opposed to the method used presently which would pick up any difference 
between the two distinct age groups.  Therefore, the difference in the findings 
between the current study and the study of Tsang et al. may be due to the use of 
different statistical methods.  It is also possible that the difference may be related 
to the different population samples as the current study was conducted in the 
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United States of America and the study of Tsang et al. was conducted in China.  
In an abstract by Duncan et al., no correlation between age and exhaled NO was 
found in a group of 59 healthy individuals.12  However, this study had a limited 
age range with the oldest category reaching a peak of 60 years. Also, there were 
only two individuals in the oldest age category of “51-60.”  In addition, the “off-
line” technique was used which differed from the “on-line” technique used in the 
present study. 
 The mechanisms responsible for the elevated NO concentrations in the 
older population are not clear at present.  This study showed a difference in 
exhaled NO concentrations between the age groups despite similar pHs between 
the groups.  Therefore, this is more compatible with a NOS-mediated increase 
rather than an airway pH-mediated increase in NO.  If indeed the elevated NO 
concentration is due to NOS, what is the underlying reason for the increased 
NOS activity and what type of NOS is responsible? 
 It has been proposed that aged individuals have a baseline airway 
inflammation despite being clinically healthy.12, 65, 66  Bronchoalveolar lavage 
examination has supported this hypothesis by showing that older individuals 
have elevated lymphocytes with an elevated CD4+/CD8+ T cell ratio, elevated 
IgM, IgA, and IgG levels, elevated IL-6 and IL-8, and elevated neutrophils.5  It is 
therefore possible that a low-grade inflammation may provide the necessary 
constituents such as inflammatory cytokines to induce the expression of iNOS in 
bronchial epithelial cells, macrophages, and neutrophils leading to the elevated 
NO levels in the older population.   
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Another potential reason for the elevated NO concentrations in the older 
population may be due to an immune system dysregulation without inflammation 
leading to inappropriate NOS (iNOS or cNOS) expression.   
It is also possible that NO concentrations are elevated at baseline in the 
aged in an attempt to compensate for an impaired immune system as NO has 
been shown to be toxic to microorganisms and therefore may be of assistance to 
the immune system.  This baseline compensatory increase could potentially be 
mediated by elevated cNOS or iNOS expression.   
Lastly, the increase in NO concentrations in older individuals may be 
secondary to an incompetent soft palate allowing for contamination of exhaled 
lower airway NO with upper airway NO despite performing the maneuver 
properly. 
 The significance of the elevated NO concentrations in the aged population 
is not clear.  Whether the elevated levels further support the hypothesis of 
baseline airway inflammation in the aged remains to be determined.  If the 
elevated NO levels are due to an immune system dysregulation or a 
compensatory mechanism to assists an impaired immune system then NO levels 
may be useful in identifying those with immune systems which are not completely 
competent to fight infection.  If this is indeed the case, an elevated NO 
concentration may serve as a marker for a dysregulated or impaired immune 
system which would predispose older individuals to pulmonary infections such as 
pneumonia with poorer outcomes.  Finally, it is possible that the difference in NO 
concentration between the older and younger groups is not clinically significant.  
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Additional investigations are necessary to elucidate the mechanisms and 
significances of elevated NO levels in the aged.  A study which employed 
immunohistochemical methods to determine the differential expression of the 
NOSs between the age groups would elucidate which NOS is responsible for the 
elevated NO concentrations in the aged.  Another study of value would be to 
create a prospective study in which baseline serial measurements of NO would 
be taken in an older population while they are free of respiratory disease.  The 
group would then be followed for the incidence of pulmonary infections along with 
the morbidity and mortality secondary to pulmonary infections in order to 
determine if a relationship exists between baseline elevated NO levels and 
pulmonary infections in the aged.  An additional study that would be interesting 
would be to determine the effect of baseline inflammation in the aged on NO 
levels.  This could be accomplished by performing bronchoscopic biopsy 
evaluations for inflammation in younger and older individuals and correlating the 
levels of inflammation with the exhaled NO concentrations.  Another potentially 
valuable study would be to perform bronchoalveolar lavages or induced sputum 
studies on older and younger individuals to assess the milieu of cells and 
mediators and their relationships with exhaled NO concentrations. 
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Conclusion 
 
 This study evaluated exhaled NO levels between younger and older 
populations to gain further insight into possible differences between the airways 
of these two groups.  It was found that older individuals have significantly higher 
NO concentrations than younger individuals despite each group having similar 
pHs.  The reasons for this difference along with the relationship to pulmonary 
infections are unclear and further studies will be necessary to further evaluate 
these issues.   
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Appendix A: Exhaled Breath Condensate and Exhaled Breath Nitric Oxide Study 
Questionnaire 
 
 
Subject number:_______ 
 
Exhaled Breath Condensate and exhaled Breath Nitric 
Oxide Study Questionnaire 
 
 
Today’s Date _______________________________________ 
 
Gender: Male Female (circle one) 
 
1) How old are you? ______________years 
2)   Do you have any health problems that you see a physician for? Please list them 
below. 
 
                     1._________________________________________________________ 
                      
 
                     2. ________________________________________________________ 
 
                         
                     3. ________________________________________________________ 
 
 
                     4. ________________________________________________________ 
 
 
                      5.________________________________________________________ 
 
 
3) Are you taking any medications?  If so please list them below. (Including over the 
counter medications) 
 
 
                     1._________________________________________________________ 
                      
 
                     2. ________________________________________________________ 
 
                         
                     3. ________________________________________________________ 
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Appendix A (Continued) 
 
 
 
                     4. ________________________________________________________ 
 
 
                      5.________________________________________________________ 
 
 
4) If you have ever smoked, answer the following. 
 
 
                     How many packs per day did you smoke? ________________________ 
 
 
                     For how many years did you smoke? ____________________________ 
 
 
                     When did you stop smoking? __________________________________ 
 
 
 
5) On what date were you last ill? _________________________________________ 
 
 
 
6) What illness did you have? ____________________________________________ 
 
 
 
7) What is your occupation? _____________________________________________ 
 
 
 
8) Are you exposed to second hand smoke at home or at work? Please circle “yes” or 
“no”. 
   
  YES      or      NO         
 
9) Were you or are you exposed to any gases, dusts, or fumes at your job? 
 
                   YES      or       NO 
 
           If so, please explain:    ____________________________________________ 
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Appendix B: Age Distributions within Each Age Category 
 
 
Category: Old 
 
Distribution: Age 
 
60
65
70
75
80
 
 
 
Quantiles 
100.0% maximum 79.000
99.5%  79.000
97.5%  79.000
90.0%  77.500
75.0% quartile 76.000
50.0% median 71.500
25.0% quartile 67.000
10.0%  63.000
2.5%  61.000
0.5%  61.000
0.0% minimum 61.000
 
Moments 
Mean 71.291667
Std Dev 5.3363329
Std Err Mean 1.0892744
upper 95% Mean 73.545002
lower 95% Mean 69.038331
N 24
 
38 
Appendix B (Continued) 
 
 
Category: Young 
 
Distribution: Age 
 
17.5
20
22.5
25
27.5
30
32.5
 
 
 
Quantiles 
100.0% maximum 30.000
99.5%  30.000
97.5%  30.000
90.0%  27.600
75.0% quartile 26.000
50.0% median 24.000
25.0% quartile 21.000
10.0%  19.400
2.5%  18.000
0.5%  18.000
0.0% minimum 18.000
 
Moments 
Mean 23.608696
Std Dev 2.9808347
Std Err Mean 0.621547
upper 95% Mean 24.897705
lower 95% Mean 22.319686
N 23
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Appendix C: Age Category and Gender Distributions for Entire Study Population 
 
 
Age Category Distribution for Entire Study Population  
 
old
young
old
young
 
 
Frequencies 
Level Count Prob
old 25 0.52083
young 23 0.47917
Total 48 1.00000
 
     2 Levels 
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Gender Distribution for Entire Study Population 
 
female
male
female
male
 
 
Frequencies 
Level Count Prob
female 25 0.52083
male 23 0.47917
Total 48 1.00000
 
     2 Levels 
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Appendix D: Distributions of Characteristics and Measurements by Age Category 
 
 
Age Category: Old 
 
 
FEV1 
 
70
80
90
100
110
120
130
 
 
 
Quantiles 
100.0% maximum 122.00
99.5%  122.00
97.5%  122.00
90.0%  116.00
75.0% quartile 101.50
50.0% median 94.00
25.0% quartile 87.50
10.0%  76.60
2.5%  73.00
0.5%  73.00
0.0% minimum 73.00
 
Moments 
Mean 94.48
Std Dev 12.467023
Std Err Mean 2.4934046
upper 95% Mean 99.626134
lower 95% Mean 89.333866
N 25
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FEV6 
 
70
80
90
100
110
120
130
 
 
 
Quantiles 
100.0% maximum 123.00
99.5%  123.00
97.5%  123.00
90.0%  109.40
75.0% quartile 103.50
50.0% median 95.00
25.0% quartile 87.50
10.0%  77.60
2.5%  77.00
0.5%  77.00
0.0% minimum 77.00
 
Moments 
Mean 95.04
Std Dev 11.570364
Std Err Mean 2.3140729
upper 95% Mean 99.816012
lower 95% Mean 90.263988
N 25
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FEV1/FEV6 
 
65
70
75
80
85
90
95
 
 
 
Quantiles 
100.0% maximum 91.000
99.5%  91.000
97.5%  91.000
90.0%  84.400
75.0% quartile 81.000
50.0% median 78.000
25.0% quartile 74.500
10.0%  70.000
2.5%  69.000
0.5%  69.000
0.0% minimum 69.000
 
Moments 
Mean 77.96
Std Dev 5.2399109
Std Err Mean 1.0479822
upper 95% Mean 80.122929
lower 95% Mean 75.797071
N 25
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Gender 
 
female
male
female
male
 
 
Frequencies 
Level Count Prob
female 11 0.44000
male 14 0.56000
Total 25 1.00000
 
     2 Levels 
 
 
Health Problems 
 
breastca
cad, bph
cad, htn, hyperlipid
gerd
htn
htn, AR, MR, hypothyroid
htn, hyperlip
htn, hyperlip, afib, bladder ca
htn, mvp
htn,gout, hypothyroid
hyperlipid
none
oa
osteopen
platelet disorder
breastcacad, bph
cad, htn, hyperlipid
gerd
htn
htn, AR, MR, hypothyroid
htn, hyperlip
htn, hyperlip, afib, bladder ca
htn, mvp
htn,gout, hypothyroid
hyperlipid
none
oa
osteopen
platelet disorder
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Frequencies 
Level Count Prob
breastca 1 0.04000
cad, bph 1 0.04000
cad, htn, hyperlipid 2 0.08000
gerd 2 0.08000
htn 4 0.16000
htn, AR, MR, hypothyroid 1 0.04000
htn, hyperlip 2 0.08000
htn, hyperlip, afib, bladder ca 1 0.04000
htn, mvp 1 0.04000
htn,gout, hypothyroid 1 0.04000
hyperlipid 1 0.04000
none 5 0.20000
oa 1 0.04000
osteopen 1 0.04000
platelet disorder 1 0.04000
Total 25 1.00000
 
    15 Levels 
 
 
Medications 
 
acupril, glucosamine, chondroitin
asa, naprosyn, hytrin
bppill, asa, ca, vitD, vitE
centrum, triamterene, ca, vitd, fosamax
ditropan, maxide
evista, vitD
feldene, oscal, vitD, premarin
fosimax, glucosamine/choldroitin, folate, vit D, ca
lipitor, cardura, alelite, plendal, vioxx
lipitor,toprol, altace, plavix, asa, ocuvit, mvi, vitc, vite, vi
mvi, vite
mvi, vite, asa
nexium, imipramine, actinal, premarin
nifedipine, vitc, vite, asa, zocor
none
norvasc, asa, mvi, vitC, vitE
pcn, prempro
premerin, protonix
prinivil, diazide, lipitor
rythmol, zocor, dig, plendil, trerazosin
synthroid, lisinopril, allopurinol
vasotec, dynacirc, lasix
verapamil, maxide, synthroid
verapamil, toprol, lipitor, asa,naproxen, viagra
voltaran, lipitor, folate, ca, vitD, MVI
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Appendix D (Continued) 
 
 
 
 
 
Frequencies 
Level Count Prob
acupril, glucosamine, chondroitin 1 0.04000
asa, naprosyn, hytrin 1 0.04000
bppill, asa, ca, vitD, vitE 1 0.04000
centrum, triamterene, ca, vitd, fosamax 1 0.04000
ditropan, maxide 1 0.04000
evista, vitD 1 0.04000
feldene, oscal, vitD, premarin 1 0.04000
fosimax, glucosamine/choldroitin, folate, vit D, ca 1 0.04000
Lipitor, cardura, alelite, plendal, vioxx 1 0.04000
lipitor,toprol, altace, plavix, asa, ocuvit, mvi, vitc, vite, vi 1 0.04000
mvi, vite 1 0.04000
mvi, vite, asa 1 0.04000
nexium, imipramine, actinal, premarin 1 0.04000
nifedipine, vitc, vite, asa, zocor 1 0.04000
none 1 0.04000
norvasc, asa, mvi, vitC, vitE 1 0.04000
pcn, prempro 1 0.04000
premerin, protonix 1 0.04000
prinivil, diazide, lipitor 1 0.04000
rythmol, zocor, dig, plendil, trerazosin 1 0.04000
synthroid, lisinopril, allopurinol 1 0.04000
vasotec, dynacirc, lasix 1 0.04000
verapamil, maxide, synthroid 1 0.04000
verapamil, toprol, lipitor, asa,naproxen, viagra 1 0.04000
voltaran, lipitor, folate, ca, vitD, MVI 1 0.04000
Total 25 1.00000
 
    25 Levels 
 
 
Smoking History 
 
no
yes
no
yes
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Frequencies 
Level Count Prob
no 9 0.36000
yes 16 0.64000
Total 25 1.00000
 
     2 Levels 
 
Packs Smoked When Smoker 
 
.
0.5cigpd
0.5ppd
1ppd
2cigpd
2pipes
2ppd
3ppd
<1ppd
na
.0.5cigpd
0.5ppd
1ppd
2cigpd
2pipes
2ppd3ppd
<1ppd
na
 
 
Frequencies 
Level Count Prob
. 1 0.04000
0.5cigpd 1 0.04000
0.5ppd 2 0.08000
1ppd 5 0.20000
2cigpd 2 0.08000
2pipes 1 0.04000
2ppd 1 0.04000
3ppd 1 0.04000
<1ppd 2 0.08000
na 9 0.36000
Total 25 1.00000
 
    10 Levels 
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Years Smoked 
 
na na
 
 
Frequencies 
Level Count Prob
na 9 1.00000
Total 9 1.00000
 
     1 Levels 
 
 
Last Ill 
 
unknown unknown
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Frequencies 
Level Count Prob
unknown 16 1.00000
Total 16 1.00000
 
     1 Levels 
 
Illness When Last Ill 
 
na
uri
na
uri
 
 
Frequencies 
Level Count Prob
na 16 0.64000
uri 9 0.36000
Total 25 1.00000
 
     2 Levels 
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Occupation 
 
nretired
nurse
prof
reseraunt
retired
transcrip
nretirednurse
prof
reseraunt
retired
transcrip
 
 
Frequencies 
Level Count Prob
nretired 1 0.04000
nurse 1 0.04000
prof 3 0.12000
reseraunt 1 0.04000
retired 18 0.72000
transcrip 1 0.04000
Total 25 1.00000
 
     6 Levels 
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Second Hand Smoke 
 
no
yes
no
yes
 
 
Frequencies 
Level Count Prob
no 22 0.88000
yes 3 0.12000
Total 25 1.00000
 
     2 Levels 
 
 
Exposures 
 
no
yes
no
yes
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Frequencies 
Level Count Prob
no 22 0.88000
yes 3 0.12000
Total 25 1.00000
 
     2 Levels 
 
 
Explanation of Exposures 
 
asbestoscourths
coaldust, cokeoven
fire fighter
na
asbestoscourthscoaldust, cokeoven
fire fighter
na
 
 
Frequencies 
Level Count Prob
asbestoscourths 1 0.04000
coaldust, cokeoven 1 0.04000
fire fighter 1 0.04000
na 22 0.88000
Total 25 1.00000
 
     4 Levels 
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NO Concentrations 
 
0
50
100
150
200
250
 
 
 
Quantiles 
100.0% maximum 214.00
99.5%  214.00
97.5%  214.00
90.0%  90.70
75.0% quartile 56.60
50.0% median 36.90
25.0% quartile 26.30
10.0%  14.44
2.5%  6.00
0.5%  6.00
0.0% minimum 6.00
 
Moments 
Mean 47.772
Std Dev 41.525038
Std Err Mean 8.3050076
upper 95% Mean 64.912693
lower 95% Mean 30.631307
N 25
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pH Deaerated 
 
5
5.5
6
6.5
7
7.5
8
8.5
 
 
 
Quantiles 
100.0% maximum 8.1200
99.5%  8.1200
97.5%  8.1200
90.0%  8.0400
75.0% quartile 7.9700
50.0% median 7.7200
25.0% quartile 7.1750
10.0%  6.5280
2.5%  5.2600
0.5%  5.2600
0.0% minimum 5.2600
 
Moments 
Mean 7.4996
Std Dev 0.6650343
Std Err Mean 0.1330069
upper 95% Mean 7.7741127
lower 95% Mean 7.2250873
N 25
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Age Category: Young 
 
 
FEV1 
 
70
80
90
100
110
120
130
 
 
 
Quantiles 
100.0% maximum 123.00
99.5%  123.00
97.5%  123.00
90.0%  112.40
75.0% quartile 100.75
50.0% median 95.00
25.0% quartile 87.50
10.0%  81.00
2.5%  80.00
0.5%  80.00
0.0% minimum 80.00
 
Moments 
Mean 95.590909
Std Dev 10.795321
Std Err Mean 2.3015702
upper 95% Mean 100.37729
lower 95% Mean 90.804532
N 22
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FEV6 
 
70
75
80
85
90
95
100
105
110
115
 
 
 
Quantiles 
100.0% maximum 111.00
99.5%  111.00
97.5%  111.00
90.0%  105.00
75.0% quartile 103.25
50.0% median 92.50
25.0% quartile 88.00
10.0%  83.60
2.5%  74.00
0.5%  74.00
0.0% minimum 74.00
 
Moments 
Mean 94.681818
Std Dev 9.0679255
Std Err Mean 1.9332882
upper 95% Mean 98.702311
lower 95% Mean 90.661325
N 22
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FEV1/FEV6 
 
70
75
80
85
90
95
100
 
 
 
Quantiles 
100.0% maximum 98.000
99.5%  98.000
97.5%  98.000
90.0%  95.400
75.0% quartile 91.000
50.0% median 87.000
25.0% quartile 81.750
10.0%  77.200
2.5%  74.000
0.5%  74.000
0.0% minimum 74.000
 
Moments 
Mean 86.545455
Std Dev 6.2467307
Std Err Mean 1.3318075
upper 95% Mean 89.3151
lower 95% Mean 83.775809
N 22
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Gender 
 
female
male
female
male
 
 
Frequencies 
Level Count Prob
female 14 0.60870
male 9 0.39130
Total 23 1.00000
 
     2 Levels 
 
 
Health Problems 
 
none
ulcerativecolitis
none
ulcerativecolitis
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Frequencies 
Level Count Prob
none 22 0.95652
ulcerativecolitis 1 0.04348
Total 23 1.00000
 
     2 Levels 
 
 
Medications 
 
bcp
doxy, bcp
imuran
none
weightlosssulp
bcp
doxy, bcp
imuran
none
weightlosssulp
 
 
Frequencies 
Level Count Prob
bcp 5 0.21739
doxy, bcp 1 0.04348
imuran 1 0.04348
none 15 0.65217
weightlosssulp 1 0.04348
Total 23 1.00000
 
     5 Levels 
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Smoking History 
 
no
yes
no
yes
 
 
Frequencies 
Level Count Prob
no 21 0.91304
yes 2 0.08696
Total 23 1.00000
 
     2 Levels 
 
 
Packs Smoked When Smoker 
 
2cigpd
3cigpd
na
2cigpd
3cigpd
na
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Frequencies 
Level Count Prob
2cigpd 1 0.04348
3cigpd 1 0.04348
na 21 0.91304
Total 23 1.00000
 
     3 Levels 
 
 
Years Smoked 
 
na na
 
 
Frequencies 
Level Count Prob
na 21 1.00000
Total 21 1.00000
 
     1 Levels 
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Last Ill 
 
unknown unknown
 
 
Frequencies 
Level Count Prob
unknown 16 1.00000
Total 16 1.00000
 
     1 Levels 
 
 
Illness When Last Ill 
 
bronchitis
gastro
na
uri
bronchitis
gastro
na
uri
 
 
63 
Appendix D (Continued) 
 
 
Frequencies 
Level Count Prob
bronchitis 1 0.04348
gastro 1 0.04348
na 16 0.69565
uri 5 0.21739
Total 23 1.00000
 
     4 Levels 
 
Occupation 
 
ce-director
facman
manager
nurse
secret
student
ce-director
facman
manager
nurse
secret
student
 
 
Frequencies 
Level Count Prob
ce-director 1 0.04348
facman 1 0.04348
manager 1 0.04348
nurse 3 0.13043
secret 1 0.04348
student 16 0.69565
Total 23 1.00000
 
     6 Levels 
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Second Hand Smoke 
 
2permo
no
yes
2permo
no
yes
 
 
Frequencies 
Level Count Prob
2permo 1 0.04348
no 21 0.91304
yes 1 0.04348
Total 23 1.00000
 
     3 Levels 
 
 
Exposures 
 
no
yes
no
yes
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Frequencies 
Level Count Prob
no 22 0.95652
yes 1 0.04348
Total 23 1.00000
 
     2 Levels 
 
Explanation of Exposures 
 
Cl2twoyrago
na
Cl2twoyrago
na
 
 
Frequencies 
Level Count Prob
Cl2twoyrago 1 0.04348
na 22 0.95652
Total 23 1.00000
 
     2 Levels 
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NO Concentations 
 
0
25
50
75
100
125
 
 
 
Quantiles 
100.0% maximum 107.00
99.5%  107.00
97.5%  107.00
90.0%  63.60
75.0% quartile 27.00
50.0% median 18.70
25.0% quartile 12.70
10.0%  9.82
2.5%  6.40
0.5%  6.40
0.0% minimum 6.40
 
Moments 
Mean 25.221739
Std Dev 23.23606
Std Err Mean 4.8450535
upper 95% Mean 35.269765
lower 95% Mean 15.173713
N 23
 
 
67 
Appendix D (Continued) 
 
 
pH Deaerated  
 
6.5
7
7.5
8
 
 
 
Quantiles 
100.0% maximum 8.1200
99.5%  8.1200
97.5%  8.1200
90.0%  8.0640
75.0% quartile 7.9100
50.0% median 7.7200
25.0% quartile 7.3000
10.0%  6.9540
2.5%  6.4400
0.5%  6.4400
0.0% minimum 6.4400
 
Moments 
Mean 7.5917391
Std Dev 0.4261845
Std Err Mean 0.0888656
upper 95% Mean 7.7760351
lower 95% Mean 7.4074431
N 23
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Appendix E: Analysis of NO and pH by Age Category 
 
 
Oneway Analysis of NO By Age Category 
 
N
O
0
50
100
150
200
old young
agecat
 
Wilcoxon / Kruskal-Wallis Tests (Rank Sums) 
Level Count Score Sum Score Mean (Mean-Mean0)/Std0 
old 25 771 30.8400 3.261 
young 23 405 17.6087 -3.261 
2-Sample Test, Normal Approximation 
S Z Prob>|Z|
405 -3.26083 0.0011
1-way Test, ChiSquare Approximation 
ChiSquare DF Prob>ChiSq
10.7004 1 0.0011
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Oneway Analysis of pH Dearate By Age Category 
 
ph
de
ar
at
e
5
5.5
6
6.5
7
7.5
8
8.5
old young
agecat
 
Wilcoxon / Kruskal-Wallis Tests (Rank Sums) 
Level Count Score Sum Score Mean (Mean-Mean0)/Std0 
old 25 615.5 24.6200 0.052 
young 23 560.5 24.3696 -0.052 
2-Sample Test, Normal Approximation 
S Z Prob>|Z|
560.5 -0.05161 0.9588
1-way Test, ChiSquare Approximation 
ChiSquare DF Prob>ChiSq
0.0038 1 0.9506
 
 
 
